CVS Health authorizes $10B share repurchase program; amends bylaws for universal proxy rules

CVS HEALTH Corp

Board approved new $10B repurchase program after exhausting 2021 authorization.
Repurchases may occur via open market, private deals, accelerated share repurchase, or derivatives.
Bylaws amended to mandate compliance with SEC Rule 14a-19 for director nominations and proxies.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CVS HEALTH Corp: Amended by-laws to revise Section 1.10 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-17).

Change: bylaw amendment
Effective: 2022-11-17

Exact text from the filing

On November 17, 2022, the Board of Directors of CVS Health Corporation (the “Company”) amended, effective immediately, the by-laws (the “By-laws”) of the Company to (a) revise Section 1.10 with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.

View on SEC.gov

Browse all governance changes →

CVS HEALTH Corp filing history →

Source: SEC EDGAR

accession 0000947871-22-001199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.